EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMPUG00000013346
Gene Symbol: ARAF
2 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000012678
Gene Symbol: ABL1
2 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSMPUG00000013236
Gene Symbol: ADAM17
2 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSMPUG00000001019
Gene Symbol: ADAMTS5
2 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSMPUG00000007782
Gene Symbol: ADRM1
2 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSMPUG00000002158
Gene Symbol: AKT1
2 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSMPUG00000017710
Gene Symbol: AKT2
2 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSMPUG00000015730
Gene Symbol: AKT3
2 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000017981
Gene Symbol: ALK
2 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSMPUG00000018309
Gene Symbol: ABCB1
2 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSMPUG00000013849
Gene Symbol: ABCC1
2 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSMPUG00000013368
Gene Symbol: ABCC8
4 Cross references
237 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).